Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation and immunotherapy join forces against tough pancreatic cancer

NCT ID NCT07312422

Disease control Sponsor: Zhejiang Provincial People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing whether adding low-dose radiation and an immunotherapy drug called pucotenlimab to standard chemotherapy can help control advanced pancreatic cancer. Ten adults with pancreatic cancer who haven't had prior immunotherapy will receive the combination. The goal is to see if the treatment shrinks tumors and improves disease control, while also identifying which patients benefit most.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-dose radiation, pucotenlimab (a PD-1 inhibitor), gemcitabine, nab-paclitaxel, oxaliplatin, irinotecan, leucovorin, and 5-FU
What this could lead to
If it works, this could point toward a new combination therapy that helps control advanced pancreatic cancer by activating the immune system.
What could go wrong
This is a very early, small trial with only 10 participants, so results may not apply widely. The combination also carries risks like immune-related side effects and chemotherapy toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, regardless of gender; * ECOG score of 0 to 1; * Patients with histologically or cytologically confirmed pancreatic malignancy; * No prior treatment with PD-1 or PD-L1 inhibitors; * Presence of a radiotherapeutically eligible target lesion (excluding bone metastases); * Subjects voluntarily participate in the study and provide signed informed consent. Exclusion Criteria: * Previous history of radiotherapy; * Uncontrolled chronic infectious or non-infectious diseases, including but not limited to: medication-refractory heart failure, poorly controlled hypertension, etc.; * Active or clinically uncontrolled severe infections; * History of psychoactive drug abuse that cannot be abstained from, or patients with psychiatric disorders; * Pregnant or lactating women, or patients of childbearing potential who are unwilling or unable to adopt effective contraceptive measures; * Other conditions deemed by the investigator as potentially affecting the conduct of the clinical study or the interpretation of study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LDRT Pancreatic cancer PD-1 inhibitor PD-L1 Proterizumab

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhejiang Provincial People's Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.